-
61
Insight into the avidity–affinity relationship of the bivalent, pH-dependent interaction between IgG and FcRn
Published 2024-12-01“…mAbs…”
Get full text
Article -
62
-
63
Charge heterogeneity of therapeutic monoclonal antibodies by different cIEF systems: views on the current situation
Published 2024-12-01“…mAbs…”
Get full text
Article -
64
Reconciling predicted and measured viscosity parameters in high concentration therapeutic antibody solutions
Published 2024-12-01“…mAbs…”
Get full text
Article -
65
-
66
Nonclinical immunogenicity risk assessment for knobs-into-holes bispecific IgG1 antibodies
Published 2024-12-01“…mAbs…”
Get full text
Article -
67
-
68
-
69
Variable domain mutational analysis to probe the molecular mechanisms of high viscosity of an IgG1 antibody
Published 2024-12-01“…mAbs…”
Get full text
Article -
70
-
71
-
72
-
73
-
74
Engineering hydrophobicity and manufacturability for optimized biparatopic antibody–drug conjugates targeting c-MET
Published 2024-12-01“…mAbs…”
Get full text
Article -
75
Engineered ipilimumab variants that bind human and mouse CTLA-4
Published 2025-12-01“…mAbs…”
Get full text
Article -
76
Sequence-based engineering of pH-sensitive antibodies for tumor targeting or endosomal recycling applications
Published 2024-12-01“…mAbs…”
Get full text
Article -
77
Antibody-epitope conjugates deliver immunogenic T-cell epitopes more efficiently when close to cell surfaces
Published 2024-12-01“…mAbs…”
Get full text
Article -
78
A TRAILR2/CDH3 bispecific antibody demonstrates selective apoptosis and tumor regression in CDH3-positive pancreatic cancer
Published 2024-12-01“…mAbs…”
Get full text
Article -
79
-
80